LeMaitre Vascular, Inc. (LMAT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

LeMaitre Vascular, Inc. (LMAT) Healthcare & Pipeline Overview

LeMaitre Vascular, Inc. designs, markets, and sells medical devices and implants for treating peripheral vascular disease globally. With a focus on specialized vascular products and a direct sales approach, the company maintains a strong position in the medical instruments and supplies sector, marked by a 72.4% gross margin.

What Is the Investment Thesis for LMAT?

The company's 72.4% gross margin and 24.3% profit margin highlight its operational efficiency and pricing power within the medical device market. A key value driver is the increasing prevalence of peripheral vascular disease, which fuels demand for LeMaitre's devices. Upcoming product launches and strategic acquisitions could further expand the company's market reach and product offerings. However, investors should be aware of potential risks, including regulatory hurdles and competition from larger medical device companies. The company's P/E ratio of 36.03 reflects investor expectations of continued growth, supported by its established market presence and consistent dividend yield of 0.79%.

Based on FMP financials and quantitative analysis

LMAT Key Highlights

Market capitalization of $1.81B, reflecting strong investor confidence in the company's market position and growth potential.

• Gross margin of 72.4%, indicating efficient operations and strong pricing power in the medical device market.
• Profit margin of 24.3%, showcasing the company's ability to convert revenue into profit.
• P/E ratio of 36.03, suggesting investor expectations of continued earnings growth.
• Dividend yield of 0.79%, providing a steady income stream for investors.

Who Are LMAT's Competitors?

LMAT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LMAT's Key Strengths?

Specialized product portfolio in vascular surgery.

• Direct sales force and established distribution network.
• Strong gross and profit margins.
• Reputation for quality and innovation.

What Are LMAT's Weaknesses?

Reliance on a niche market, making it vulnerable to shifts in demand.

• Potential for product liability claims.
• Limited brand recognition compared to larger medical device companies.
• Dependence on regulatory approvals for new products.

What Could Drive LMAT Stock Higher?

Potential FDA approval for new vascular graft technology, expanding product offerings.

• Increasing prevalence of peripheral vascular disease driving demand for existing products.
• Strategic acquisitions to expand market reach and product portfolio.

What Are the Key Risks for LMAT?

Rich valuation — a P/E of 36.03 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Regulatory changes affecting medical device approvals.
• Competition from larger medical device companies with greater resources.
• Economic downturns impacting hospital budgets and capital spending.
• Product liability claims related to device malfunctions or adverse patient outcomes.

What Are the Growth Opportunities for LMAT?

• Expansion into Emerging Markets: LeMaitre Vascular has the opportunity to expand its presence in emerging markets, where the prevalence of peripheral vascular disease is increasing due to changing lifestyles and aging populations. These markets represent a significant untapped potential for revenue growth, driven by increasing healthcare spending and improving access to medical care. A strategic focus on key regions within Asia-Pacific and Latin America could yield substantial returns within the next 3-5 years, potentially increasing overall revenue by 15-20%.
• New Product Development: Investing in research and development to introduce innovative products can drive future growth. Focusing on minimally invasive solutions and advanced materials could attract new customers and increase market share. The company could allocate 10-15% of its annual revenue to R&D, targeting specific areas such as drug-eluting balloons and advanced stent technologies. Successful product launches in the next 2-3 years could contribute to a 10% increase in annual revenue.
• Strategic Acquisitions: LeMaitre Vascular can pursue strategic acquisitions to expand its product portfolio and geographic reach. Acquiring companies with complementary technologies or established distribution networks can accelerate growth and enhance market position. Identifying targets with strong intellectual property and a proven track record in specific vascular segments could create synergies and drive long-term value. Successfully integrating 1-2 acquisitions within the next 3-5 years could increase overall revenue by 10-15%.
• Increased Focus on Training and Education: Providing comprehensive training and education programs for vascular surgeons and healthcare professionals can enhance product adoption and customer loyalty. Investing in educational resources, workshops, and online platforms can establish LeMaitre Vascular as a trusted partner and thought leader in the field. These initiatives can improve product utilization and drive repeat business, contributing to a 5-10% increase in annual revenue over the next 2-3 years.
• Leveraging Telemedicine and Remote Monitoring: Integrating telemedicine and remote monitoring technologies into its product offerings can improve patient outcomes and expand market reach. Developing solutions that enable remote monitoring of vascular health and facilitate virtual consultations can enhance patient engagement and improve access to care, particularly in underserved areas. This approach could lead to a 5-10% increase in annual revenue within the next 3-5 years, driven by increased adoption of remote healthcare solutions.

What Are LMAT's Competitive Advantages?

• Specialized product portfolio focused on niche areas within vascular surgery.
• Direct sales force providing close relationships with key customers.
• Strong brand reputation built on quality and innovation.
• Established distribution network reaching global markets.

What Does LMAT Do?

LeMaitre Vascular, Inc., founded in 1983 and headquartered in Burlington, Massachusetts, is a global provider of medical devices and implants focused on treating peripheral vascular disease. Originally named Vascutech, Inc., the company rebranded in 2001 to reflect its expanded focus. LeMaitre Vascular offers a comprehensive portfolio of products, including angioscopes, embolectomy catheters, occlusion catheters, perfusion catheters, thrombectomy catheters, carotid shunts, radiopaque tape, valvulotomes, vascular grafts, vascular and cardiac patches, and closure systems. These products are essential tools for vascular surgeons performing procedures to bypass or replace diseased arteries and remove blood clots. The company distinguishes itself through a direct sales force and distributor network, ensuring close relationships with healthcare providers and efficient market penetration. LeMaitre Vascular's commitment to innovation and quality has solidified its reputation as a trusted partner in the treatment of peripheral vascular disease, contributing to its significant market capitalization of $1.81B.

What Products and Services Does LMAT Offer?

• Designs medical devices and implants for peripheral vascular disease treatment.
• Markets and sells these devices globally through a direct sales force and distributors.
• Services and supports medical professionals using their products.
• Offers angioscopes for viewing blood vessel lumens.
• Provides embolectomy and thrombectomy catheters for removing blood clots.
• Manufactures vascular grafts and patches for repairing or replacing diseased arteries.
• Develops closure systems for attaching vessels during surgery.

How Does LMAT Make Money?

• Develops and manufactures specialized medical devices for vascular surgery.
• Sells products directly to hospitals and clinics through a direct sales force.
• Utilizes distributors to reach international markets and smaller healthcare facilities.
• Generates revenue through product sales and related services.

What Industry Does LMAT Operate In?

LeMaitre Vascular, Inc. operates within the medical instruments and supplies industry, a sector characterized by innovation and increasing demand due to an aging population and rising prevalence of chronic diseases. The market for peripheral vascular disease treatment is expected to grow, driven by technological advancements and minimally invasive procedures. LeMaitre competes with larger medical device companies and specialized vascular product manufacturers. The company's focus on niche products and direct sales model allows it to maintain a competitive edge in this dynamic landscape.

Who Are LMAT's Key Customers?

• Vascular surgeons performing procedures to treat peripheral vascular disease.
• Hospitals and clinics offering vascular surgery services.
• Interventional radiologists using catheters and other devices for minimally invasive procedures.
• Healthcare professionals involved in the diagnosis and treatment of vascular conditions.

Company Profile

LeMaitre Vascular, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Burlington, US. The company is led by CEO George W. LeMaitre. LMAT has traded publicly since 2006.

Return on equity for LeMaitre Vascular, Inc. stands at 16.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 9.9%, showing how much profit it generates from its asset base. LMAT trades at a trailing price-to-earnings ratio of 36.03, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 3.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 14.32 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.8%, the inverse of the P/E and a quick read on earnings relative to price.

LMAT Valuation & Market Position

With a $1.81B market cap, LeMaitre Vascular, Inc. sits in the small-cap segment of the market. Analyst price targets span from $95.00 to $135.00, with a consensus of $115.00. At the current price of $79.10, that implies approximately 45% upside potential. Relative to its peer group, LMAT's quantitative score of 90/100 is above the peer average of 64/100.

Quarterly Financial Performance: LeMaitre Vascular, Inc.

Revenue for LeMaitre Vascular, Inc. came in at $70.4M during Q2 FY2026, a 5.8% improvement versus the preceding quarter. The company recorded net income of $17.1M, with diluted EPS of $0.70. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, LMAT averaged $0.69 in diluted EPS.

LeMaitre Vascular, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 7.10 places it in the safe zone, indicating low near-term bankruptcy risk.

LeMaitre Vascular, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 2.3% above estimates on average.

Over the past six months, LeMaitre Vascular, Inc. insiders filed 100 SEC Form 4 transactions — 2 sales and 98 purchases. On net that is roughly 12K shares disposed (about $0), a signal worth weighing alongside the fundamentals.

LMAT Financials

LMAT Latest News

LMAT Analyst Consensus

LMAT MoonshotScore

Latest LeMaitre Vascular, Inc. Analysis

LMAT Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources